Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
Protagenic Therapeutics appointed Bill Nichols Jr. as President, adding over two decades of commercial experience to prepare for the Phase 2 enrollment of lead asset PT00114 in 2026. The company simultaneously streamlined its management structure, with CFO Alexander Arrow transitioning out of the role; no new CFO will be appointed immediately.
Key figures
- Drug Name
- PT00114
- Phase Of Trial
- Phase 2
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.